Patents by Inventor Ralph Michael Linden

Ralph Michael Linden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADENO-ASSOCIATED VIRUS VECTOR
    Publication number: 20240124894
    Abstract: Disclosed herein is a recombinant adeno-associated virus (AAV) vector comprising (a) a variant AAV2 capsid protein, wherein the variant AAV2 capsid protein comprises at least four amino acid substitutions with respect to a wild type AAV2 capsid protein; wherein the at least four amino acid substitutions are present at the following positions in an AAV2 capsid protein sequence: 457, 492, 499 and 533; and (b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.
    Type: Application
    Filed: October 16, 2023
    Publication date: April 18, 2024
    Inventor: Ralph Michael LINDEN
  • Adeno-associated virus vector
    Patent number: 11802293
    Abstract: Disclosed herein is a recombinant adeno-associated virus (AAV) vector comprising (a) a variant AAV2 capsid protein, wherein the variant AAV2 capsid protein comprises at least four amino acid substitutions with respect to a wild type AAV2 capsid protein; wherein the at least four amino acid substitutions are present at the following positions in an AAV2 capsid protein sequence: 457, 492, 499 and 533; and (b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: October 31, 2023
    Assignees: KING'S COLLEGE LONDON, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventor: Ralph Michael Linden
  • VIRAL PARTICLES FOR USE IN TREATING TAUOPATHIES SUCH AS ALZHEIMER'S DISEASES BY GENE THERAPY
    Publication number: 20230277687
    Abstract: The present disclosure relates to viral particles for use in treating tauopathies, particularly Alzheimer's disease, by gene therapy. More specifically, the present invention relates to a viral particle for use in treating tauopathies by gene therapy in a subject in need thereof, said viral particle comprising a nucleic acid construct including a transgene encoding a glucocerebro sidase.
    Type: Application
    Filed: August 6, 2021
    Publication date: September 7, 2023
    Inventors: Gloria GONZÁLEZ-ASEGUINOLAZA, Diego SUCUNZA GUIBERT, José Luis LANCIEGO PÉREZ, Ralph Michael LINDEN
  • VIRAL PARTICLES FOR USE IN TREATING SYNUCLEINOPATHIES SUCH AS PARKINSON'S DISEASES BY GENE THERAPY
    Publication number: 20220298528
    Abstract: The present disclosure relates to viral particles for use in treating synucleinopathies, particularly sporadic Parkinson Diseases by gene therapy. More specifically, the present invention relates to a viral particle for use in treating synucleinopathy by gene therapy in a subject in need thereof, said viral particle comprising a nucleic acid construct including a transgene encoding a glucocerebrosidase.
    Type: Application
    Filed: August 6, 2020
    Publication date: September 22, 2022
    Inventors: Gloria GONZALEZ ASEGUINOLAZA, José Luis LANCIEGO PEREZ, Ralph Michael LINDEN
  • ADENO-ASSOCIATED VIRUS VECTOR
    Publication number: 20220106612
    Abstract: Disclosed herein is a recombinant adeno-associated virus (AAV) vector comprising (a) a variant AAV2 capsid protein, wherein the variant AAV2 capsid protein comprises at least four amino acid substitutions with respect to a wild type AAV2 capsid protein; wherein the at least four amino acid substitutions are present at the following positions in an AAV2 capsid protein sequence: 457, 492, 499 and 533; and (b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.
    Type: Application
    Filed: September 3, 2021
    Publication date: April 7, 2022
    Inventor: Ralph Michael LINDEN
  • ADENO-ASSOCIATED VIRUS VECTOR
    Publication number: 20210238631
    Abstract: Disclosed herein is a recombinant adeno-associated virus (AAV) vector comprising (a) a variant AAV2 capsid protein, wherein the variant AAV2 capsid protein comprises at least four amino acid substitutions with respect to a wild type AAV2 capsid protein; wherein the at least four amino acid substitutions are present at the following positions in an AAV2 capsid protein sequence: 457, 492, 499 and 533; and (b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.
    Type: Application
    Filed: October 16, 2020
    Publication date: August 5, 2021
    Inventor: Ralph Michael Linden
  • ADENO-ASSOCIATED VIRUS VECTOR
    Publication number: 20180135076
    Abstract: Disclosed herein is a recombinant adeno-associated virus (AAV) vector comprising (a) a variant AAV2 capsid protein, wherein the variant AAV2 capsid protein comprises at least four amino acid substitutions with respect to a wild type AAV2 capsid protein; wherein the at least four amino acid substitutions are present at the following positions in an AAV2 capsid protein sequence: 457, 492, 499 and 533; and (b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.
    Type: Application
    Filed: February 17, 2015
    Publication date: May 17, 2018
    Inventor: Ralph Michael Linden